Modified serine protease inhibitors for use in the treatment of bleeding disorders
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- CAMBRIDGE ENTERPRISE LTD
- Publication Date
- 2019-08-23
Smart Images

Figure 1 
Figure 2 
Figure 3
Abstract
Description
technical field
[0001] The present invention relates to modified serine protease inhibitor (serpin) molecules with altered specificity, in particular modified to have anticoagulant protease (anticoagulant protease, anticoagulant protease) (such as activated protein C (activated protein C) , a serine protease inhibitor molecule of increased specificity of activated Protein C) (APC)). Background technique
[0002] Hemophilia is a bleeding disorder caused by a lack of circulating plasma fVIII (hemophilia A, HA) or fIX (hemophilia B, HB) (reviewed in Bolton-Maggs & Pasi, 2003). This reduces the activity of endogenous X enzyme (tenase) (Xase) and thereby reduces the amount of thrombin produced when tissue damage occurs. This leads to uncontrolled bleeding after injury as well as spontaneous bleeding to joints and soft tissues.
[0003] Hemophilia affects about 1 in 5,000 people. The 170,000 patients identified in the World Federation of Hemophilia Global Survey is an underesti...